VESOMNI is a prescription medication specifically designed for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in men, particularly those who experience concurrent lower urinary tract symptoms (LUTS). It is a combination drug that contains two active ingredients: solifenacin succinate, which is an antimuscarinic agent that helps to relax the bladder muscles, and tamsulosin hydrochloride, an alpha-blocker that aids in relaxing the muscles in the prostate and bladder neck, making it easier to urinate. VESOMNI works by addressing both the dynamic and static components of BPH, offering relief from symptoms such as difficulty in starting urination, weak stream, and the need to urinate frequently or urgently. It is typically prescribed when symptoms have not been adequately managed by a single-agent therapy. Patients are advised to follow their healthcare provider's instructions closely when taking VESOMNI, including any dietary or activity restrictions.